144: Filer Information

Filer CIK

0001778071

Filer CCC

XXXXXXXX

Is this a LIVE or TEST Filing?

LIVE

TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

Rapport Therapeutics, Inc.

SEC File Number

001-42121

Address of Issuer

99 HIGH STREET
SUITE 2100
BOSTON
MASSACHUSETTS
02110

Phone

857-321-8020

Name of Person for Whose Account the Securities are To Be Sold

Third Rock Ventures V, L.P.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

Common

Raymond James & Associates
880 Carillon Parkway
St. Petersburg � FL � 33716

5018

202254.50

47826929

05/08/2026

NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

Common

02/21/2023

Original Issuance

Issuer

2803200

02/21/2023

Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller

Title of Securities Sold

Date of Sale

Amount of Securities Sold

Gross Proceeds

Third Rock Ventures V, L.P
201 Brookline Ave
Ste 1401
Boston � MA � 02215

Common

04/17/2026

426005

17175115.78

Third Rock Ventures V, L.P
201 Brookline Ave
Ste 1401
Boston � MA � 02215

Common

05/07/2026

271495

47826929.00

144: Remarks and Signature

Remarks

Date of Notice

05/08/2026

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

11/21/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Third Rock Ventures V L.P.

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

SEC Form 144 filed by Rapport Therapeutics Inc.